CSL is a global biotechnology leader driven by a promise to save and improve lives that has endured for over a century. Established in Australia in 1916 as Commonwealth Serum Laboratories, CSL was formed to service the health needs of a nation isolated by war, providing rapid access to critical medical advances including insulin, penicillin, and vaccines. Today, CSL delivers on this founding promise through a dynamic portfolio of lifesaving medicines that treat rare and serious diseases, prevent influenza through vaccines, and address iron deficiency and nephrology conditions.
The company operates through three principal businesses: CSL Behring, a global leader in biotherapies for rare and serious diseases with the broadest range of plasma-derived and recombinant therapies; CSL Seqirus, one of the world's largest influenza vaccine providers and the only company with singular global focus on influenza prevention; and CSL Vifor, a leader in iron deficiency and nephrology therapies. Supporting these operations is CSL Plasma, the world's largest plasma collection network with close to 350 centers across the U.S., Europe, and China. CSL employs over 29,000 people across more than 100 countries, investing billions in R&D to advance a product pipeline focused on plasma protein technology, recombinant technology, cell and gene therapy, and vaccines technology.